Tolerizing Vectors for Muscular Dystrophy Gene Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Gene therapy for muscular dystrophy faces significant setbacks due to host immune reactions, which hinder the efficacy of replacing dystrophin genes in human clinical trials, particularly in Duchenne and Becker muscular dystrophy patients.
Innovation Solution
Administration of a tolerizing vector that induces immunological tolerance to specific antigens associated with the gene therapy vector, reducing immune stimulation and suppressing the host immune response, thereby improving the efficacy of muscular dystrophy gene therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a replacement gene is administered to treat muscular dystrophy, then the therapeutic effect is improved, but the host immune response increases
Solution Approach 1:
The patent introduces a tolerizing vector as an intermediary that delivers immunosuppressive molecules (such as CTLA-4Ig, PD-1Ig, or TGF-beta) to suppress the host immune response. This mediator bridges the gap between the replacement gene therapy and the immune system, allowing therapeutic gene delivery while preventing harmful immune reactions against the transgene or vector.
Solution Approach 2:
The tolerizing vector is administered before or concurrently with the replacement gene vector to pre-condition the immune system. By delivering immunosuppressive molecules in advance, the host immune response is suppressed before it can mount a harmful reaction against the replacement gene therapy, enabling successful gene delivery and expression.
2Reliability
If gene therapy is administered to replace dystrophin genes, then the treatment efficacy is improved, but the immune stimulation increases
Solution Approach 1:
The patent converts the harmful immune stimulation into a beneficial effect by using the immune system's response to the vector as a target for immunosuppression. The tolerizing vector specifically targets and suppresses the immune response against the gene therapy vector and transgene, transforming the harmful immune stimulation into a controlled state that allows sustained therapeutic expression.
3Reliability
If replacement gene therapy is used for Duchenne and Becker muscular dystrophy, then the disease treatment is improved, but the host immune reaction increases
Solution Approach 1:
The patent changes the immunological parameters of the host by introducing immunosuppressive molecules through the tolerizing vector. This alters the immune system's state from a reactive, harmful condition to a tolerant, suppressed state, allowing the replacement gene therapy to function effectively without being rejected by the host immune system.
Data Source
AI summary
The instant disclosure provides replacement gene tolerizing vectors and methods of using such vectors for treating individuals receiving gene therapy for muscular dystrophy, e.g., Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), etc. Aspects of the methods include administering to the individual, in need thereof, an effective amount of a gene therapy tolerizing vaccine composition that includes a replacement gene tolerizing vector to reduce one or more symptoms of a subject's immune response to gene therapy treatment for muscular dystrophy and/or improve the efficacy of the gene therapy. Compositions and kits for practicing the methods of the disclosure are also provided.